Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 331-336

  Van den Wyngaert, Tim ^a   Claeys, T ^b   Huizing, M T ^a   Vermorken, J B ^a   Fossion, E ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b ZNA Middelheim ^*  (Belgium)

Author keywords

Bisphosphonates; Jaw; ONJ; Osteonecrosis; Outcome study

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTHRACYCLINE; ANTIANDROGEN; ANTIBIOTIC AGENT; ANTIESTROGEN; ANTIMETABOLITE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CHLORHEXIDINE; CLINDAMYCIN; DOXYCYCLINE; GONADORELIN AGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID; PARACETAMOL; PLATINUM COMPLEX; TAXANE DERIVATIVE; THALIDOMIDE; VINCA ALKALOID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE NECROSIS; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRACTURE HEALING; HUMAN; JAW DISEASE; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; TOOTH EXTRACTION; TREATMENT DURATION;

EID: 60549109454     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn630     Document Type: Article

References (19)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61(9): 1115-1117.
2. Devogelaer JP. Clinical use of bisphosphonates. Curr Opin Rheumatol 1996; 8(4): 384-391.
3. Ross JR, Saunders Y, Edmonds PM et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003; 327(7413): 469-474.
4. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65(3): 369-376.
5. Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: Cause and effect or a post hoc fallacy? Ann Oncol 2006; 17(8): 1197-1204.
6. Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23(6): 826-836.
7. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005; 23(34): 8580-8587.
8. Wang EP, Kaban LB, Strewler GJ et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65(7): 1328-1331.
9. Van den Wyngaert T. Osteonecrosis of the jaw (ONJ) might explain the increased oral surgery risk in cancer patients treated with bisphosphonates. J Evid Based Dent Pract 2007; 7(3): 132-135.
10. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144(10): 753-761.
11. Van den Wyngaert T, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 2007; 19(4): 315-322.
12. Ruggiero S, Gralow J, Marx R et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2(1): 7-14.
13. Landau S, Everitt B. Survival analysis. In Landau S, Everitt B (eds): A Handbook of Statistical Analyses Using SPSS. Boca Raton, FL: Chapman & Hall/CRC Press 2004; 245-276.
14. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9 (Suppl 4): 28-37.
15. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004; 11(2): 207-224.
16. Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007; 356(10): 1075-1076.
17. Freiberger JJ, Padilla-Burgos R, Chhoeu AH et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: A case series. J Oral Maxillofac Surg 2007; 65(7): 1321-1327.
18. Agrillo A, Petrucci MT, Tedaldi M et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws. J Craniofac Surg 2006; 17(6): 1080-1083.
19. Vescovi P, Merigo E, Manfredi M et al. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. Photomed Laser Surg 2008; 26(1): 37-46.